The stock of Mesoblast Ltd ADR (NASDAQ:MESO) last traded at $3.49, down -11.20% from the previous session.
MESO stock price is now 69.33% away from the 50-day moving average and -0.77% away from the 200-day moving average. The market capitalization of the company currently stands at $397.86M.
, while ‘William Blair’ rates the stock as ‘Mkt Perform’
During the past 12 months, Mesoblast Ltd ADR has had a low of $1.61 and a high of $10.24. As of last week, the company has a debt-to-equity ratio of 0.24, a current ratio of 2.71, and a quick ratio of 2.71. The fifty day moving average price for MESO is $2.0944 and a two-hundred day moving average price translates $3.4625 for the stock.
The latest earnings results from Mesoblast Ltd ADR (NASDAQ: MESO) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at -$0.28, beating analysts’ expectations of -$0.31 by 0.03. This compares to -$0.24 EPS in the same period last year. The net profit margin was -1061.43% and return on equity was -16.40% for MESO.
Mesoblast Ltd ADR(MESO) Company Profile
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
